Skip to main content
Clinical Trials/NCT03728998
NCT03728998
Completed
Not Applicable

Can Non-invasive Measurement of Cardiac Index, Stroke Volume and Systemic Vascular Resistance Contribute to Better Tailoring of Treatment in Patients Presenting With Sepsis to the ED?

Medical Centre Leeuwarden1 site in 1 country31 target enrollmentMay 1, 2018
ConditionsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Medical Centre Leeuwarden
Enrollment
31
Locations
1
Primary Endpoint
The percentage of subjects in whom a passive leg raise test resulted in a 15% or more improvement in cardiac index measured by the Clearsight non-invasive hemodynamic monitoring system.
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Little is known about the optimal fluid therapy of patients with uncomplicated sepsis. Most recommendations are extrapolated from studies performed in patients with septic shock. Therefore, it is unknown how effective our current fluid therapy is. Furthermore, current therapy is not tailored to individual needs. The aim of the current study is to investigate the added value of non-invasive measurements of (dynamic) circulatory parameters in the treatment of a convenience sample of sepsis patients presenting to the ED.

Registry
clinicaltrials.gov
Start Date
May 1, 2018
End Date
March 23, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medical Centre Leeuwarden
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • At presentation in the ED:
  • there has to be evidence of an infection: -temp \<36 or \>38 without an obvious cause for hypo-or hyperthermia
  • There has to be evidence of organ dysfunction by the presence of at least one of the following criteria: altered mental state, hypoxia (spo2\<94% or 5% lower than baseline), lactate \>2 mmol/l in ABGA or VBGA directly drawn after presentation, hypotension (MAP\<65 mmHg or SBP\<100mmHg), or a respiratory rate\>22/min.

Exclusion Criteria

  • Patients with septic shock (i.e. who remained hypotensive after fluid bolus administration, needing vasopressor therapy to obtain a MAP\>65 in the presence of a lactate \>
  • (i.e. septic shock) These will be excluded afterwards, but will be shown in an inclusion flowchart.
  • Subjects for whom it is impossible to obtain a reliable signal for Clearsight measurements.
  • Increased abdominal pressures
  • Need for immediate ventilatory support or surgery
  • Presence of an acute cerebral event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, active gastrointestinal bleed, trauma
  • Known metastatic cancer
  • Pregnancy

Outcomes

Primary Outcomes

The percentage of subjects in whom a passive leg raise test resulted in a 15% or more improvement in cardiac index measured by the Clearsight non-invasive hemodynamic monitoring system.

Time Frame: 1 hour

3 baseline readings will be done for CI separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CI will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CI is done. A difference of 15% or more is found to be clinically significant.

Secondary Outcomes

  • The ability of non-invasively measured baseline CO, CI, SVR and SV to predict fluid-responsiveness correctly (measurements by the Clearsight non-invasive hemodynamic monitoring system).(1 hour)

Study Sites (1)

Loading locations...

Similar Trials